Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020


Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer's and other degenerative diseases, today announced Casey Lynch, the company's chief executive officer, chair, and co-founder will present at the 3rd Annual Neuroscience Innovation Forum on Sunday, January 12, 2020 at 3:45 p.m. PST / 6:45 p.m. EST. The Forum will take place on the eve of the J.P. Morgan Healthcare Conference in downtown San Francisco.

A live webcast of the corporate presentation will be accessible at the Investor Calendar page under the News & Events heading of the Cortexyme investor site (ir.cortexyme.com). The webcast will be archived at that location for 90 days.

In addition to the corporate presentation, Ms. Lynch will participate in a plenary session at the Forum, "Advances in Alzheimer's & Other Cognitive Disorders," earlier in the day. This event will feature brief presentations from a panel of neuroscience drug development experts followed by a roundtable discussion moderated by co-chairs Christian Jung, Partner at the Dementia Discovery Fund, and Sumant Kulkarni, Managing Director of Biotechnology Equity Research at Canaccord Genuity LLC.

About Cortexyme, Inc.

Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer's disease and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer's patients and tied to neurodegeneration and neuroinflammation in animal models. The company's lead investigational medicine, COR388, is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in patients with mild to moderate Alzheimer's. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Forward-looking statements are based on Cortexyme's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the final prospectus related to Cortexyme's initial public offering filed with the Securities and Exchange Commission on May 9, 2019 and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2019. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.


These press releases may also interest you

at 16:35
AVROBIO, Inc. , a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pandemic and a current assessment of the impact on AVROBIO's...

at 16:30
An economic crisis can strike anytime, and the latest black swan event that we've entered is the best proof. Such an unpredictable and unforeseen event, unfortunately, comes with some extreme consequences, and people have to prepare for bleak times....

at 16:30
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the...

at 16:25
Canon U.S.A., Inc., a leader in digital imaging solutions, announced today that they will be hosting a Virtual Press Conference to unveil the company's new professional imaging products and technologies. The Virtual Press Conference, which will be...

at 16:15
QSC announces the opening of QSC Netherlands BV, effective April 1, 2020. Based in Geldermalsen, QSC Netherlands BV will serve as the business development hub for Live Sound & Systems in the Benelux region as well as house QSC's EMEA service repair...

at 16:15
INVO Bioscience, Inc. , a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results...



News published on 8 january 2020 at 16:10 and distributed by: